• Search Faculty Directory Again
  • Photo: Jenna Hart Burton

    Jenna Hart Burton
    Associate Professor of Clinical and Associate Researcher and Assistant Research Scientist
    Surgical & Radiological Sciences

    131 CCAH
    Davis, CA 95616


    jhburton@ucdavis.edu

       

    Research Focus

    Comparative and translational oncology, canine lymphoma

    Specialty Focus

    Veterinary medical oncology

    Education

    1994 BA Biology, Bowdoin College, Brunswick, Maine
    2006 DVM Veterinary Medicine, The Ohio State University, Columbus, Ohio
    2011 MS Medical Oncology, Colorado State University, Fort Collins, CO

    Honors and Awards

    2012 Phi Zeta Clinical Sciences Research Award
    2011 Resident Research Abstract Award, ACVIM Forum, Denver, Colorado
    2009 Outstanding Resident, Phi Zeta Honor Society, Colorado State University
    2008 Outstanding Specialty Resident, SCAVMA, Colorado State University
    2007 Outstanding Small Animal Intern SCAVMA, Colorado State University
    2006 Excellence in Ophthalmology Student Award, The Ohio State University College of Veterinary Medicine
    2006 Excellence in Small Animal Medicine Student Award, The Ohio State University College of Veterinary Medicine
    2006 American Association of Feline Practitioners Senior Student Award, The Ohio State University College of Veterinary Medicine
    1993 Franklin Delano Roosevelt Award, Bowdoin College

    Licenses

    Diplomate, American College of Veterinary Internal Medicine (Oncology)
    California veterinary license (#20646)

    Active Research Grants

    Principal Investigator, K12 Paul Calabresi Career Development Award: Contributions of B-cell Lymphoma Microenvironment in the Development of Drug Resistance, (Principal Investigator),

    Principal Investigator, COTC 021/022: Evaluation of Orally Administered mTOR inhibitor Rapamycin in Dogs in the Adjuvant Setting with Osteosarcoma, (Principal Investigator), Morris Animal Foundation

    Co-Principal Investigator, Use of diphenhydramine to reduce infusion-related ventricular arrhythmias in dogs treated with doxorubicin, Joshua Stern (Principal Investigator), Center for Companion Animal Health

    Principal Investigator, Pharmacokinetics of oral chlorambucil in cancer-bearing cats, (Principal Investigator), UC Davis Center for Companion Animal Health

    Co-Investigator, Evaluation of transarterial embolization of hepatic neoplasia, William T.N. Culp (Principal Investigator), UC Davis Center for Companion Animal Health

    Co-Investigator, Outcome and Transrectal Ultrasound use in Canine Urethral Stent Cases, William T.N. Culp (Principal Investigator), UC Davis Center for Companion Animal Health

    Co-Investigator, Evaluation of miRNA Concentrations in Dogs with Prostate Neoplasia, William T.N. Culp (Principal Investigator), UC Davis Center for Companion Animal Health

    Co-Investigator, Use of prostatic aspirate culture to identify bacterial infection in dogs with prostatic neoplasia, Katherine Skorupski (Principal Investigator), UC Davis Center for Companion Animal Health

    Co-Investigator, Pharmacokinetic analysis of vinblastine in tumor bearing cats and analysis of population covariates, Luke Wittenburg (Principal Investigator), UC Davis Center for Companion Animal Health

    Principal Investigator, Enhanced Tumor Permeation and Retention of a Nanoformulation of Doxorubicin, (Principal Investigator), UC Davis Center for Companion Animal Health

    Most Recent 10 Publications

    • Jenna Hart Burton: Association of surgical approach with complication rate, 
progression-free survival time, and disease-specific 
survival time in cats with mammary adenocarcinoma: 
107 cases (1991–2014) 2018 Gemignani F, Mayhew PD, Giuffrida MA, Palaigos J, Runge JJ, Holt DE, Robertson NA, Seguin B, Walker M, Singh A, Liptak JM, Romanelli G, Martano M, Boston SE, Lux C, Busetto R, Culp WTN, Skorupski KA, Burton JH Association of surgical approach with complication rate, progression-free survival time, and disease-specific survival time in cats with mammary adenocarcinoma: 107 cases (1991–2014) Journal of the American Veterinary Medical Association,
    • Jenna Hart Burton: Patient characteristics, prognostic factors and outcome of dogs with high-grade primary mediastinal lymphoma 2018 Moore EL, Vernau W, Rebhun RB, Skorupski KA, Burton JH Patient characteristics, prognostic factors and outcome of dogs with high-grade primary mediastinal lymphoma Veterinary and Comparative Oncology,
    • Jenna Hart Burton: Association of cancer-related mortality, age and gonadectomy in golden retriever dogs at a veterinary academic center (1989-2016) 2018 Kent MS, Burton JH, Dank G, Bannasch DL, Rebhun RB Association of cancer-related mortality, age and gonadectomy in golden retriever dogs at a veterinary academic center (1989-2016) PLOS ONE,
    • Jenna Hart Burton: BCL2 and MYC are expressed at high levels in canine diffuse large B-cell lymphoma but are not predictive for outcome in dogs treated with CHOP chemotherapy 2017 Curran KM, Schaffer PA, Frank CB, Lana SE, Hamil LE, Burton JH, Bromberek JL, Ehrhart EJ, Avery PR BCL2 and MYC are expressed at high levels in canine diffuse large B-cell lymphoma but are not predictive for outcome in dogs treated with CHOP chemotherapy Veterinary and Comparative Oncology,
    • Jenna Hart Burton: Potency and stability of compounded formulations of chlorambucil, melphalan and cyclophosphamide 2017 Burton JH, Knych HK, Stanley SD, Rebhun RB Potency and stability of compounded formulations of chlorambucil, melphalan and cyclophosphamide Veterinary and Comparative Oncology,
    • Jenna Hart Burton: Clinical presentation, treatment and outcome in 31 dogs with presumed colorectal lymphoma (2001-2013) 2017 Demas I, Burton JH, Post G, Kristal O, Gauthier M, Borrego JF, Di Bella A, Lara-Garcia A Clinical presentation, treatment and outcome in 31 dogs with presumed colorectal lymphoma (2001-2013) Veterinary and Comparative Oncology,
    • Jenna Hart Burton: Expression of phosphorylated KIT in canine mast cell tumor 2017 Halsey CH, Thamm DH, Weishaar KM, Burton JH, Charles JB, Gustafson DL, Avery AC, Ehrhart EJ Expression of phosphorylated KIT in canine mast cell tumor Veterinary Pathology,
    • Jenna Hart Burton: Chemotherapy effectiveness and mortality prediction in surgically treated osteosarcoma dogs: A validation study 2016 Schmidt AF, Nielen M, Withrow SJ, Selmic LE, Burton JH, Klungel OH, Groenwold RH, Kirpensteijn J Chemotherapy effectiveness and mortality prediction in surgically treated osteosarcoma dogs: A validation study Preventive Veterinary Medicine,
    • Jenna Hart Burton: A comparative oncology study of Iniparib defines its pharmacokinetic profile and biological activity in a naturally-occurring canine cancer model. 2016 Saba C, Paoloni M, Mazcko C, Kisseberth W, Burton JH, Smith A, Wilson-Robles H, Allstadt S, Vail D, Henry C, Lana S, Ehrhart EJ, Charles B, Kent M, Lawrence J, Burgess K, Borgatti A, Suter S, Woods P, Gordon I, Vrignaud P, Khanna C, LeBlanc AK A comparative oncology study of Iniparib defines its pharmacokinetic profile and biological activity in a naturally-occurring canine cancer model. PLoS One,
    • Jenna Hart Burton: Frequency and severity of neutropenia associated with food and drug administration approved and compounded formulations of lomustine in dogs with cancer 2016 Burton JH, Stanley SD, Knych HK, Rodriguez CO, Skorupski KA, Rebhun RB Frequency and severity of neutropenia associated with food and drug administration approved and compounded formulations of lomustine in dogs with cancer Journal of Veterinary Internal Medicine,

    Most Recent 5 Book Chapters

    2014 Burton JH, Khanna C: The role of clinical trials in veterinary oncology, Smith A, (ed), Veterinary Clinics of North America. 977-87.

    2011 Burton JH: Chemotherapy for the feline cancer patient, Little S, (ed), The Cat: Clinical Medicine and Management, St. Louis, MO. .